These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11396878)

  • 1. Specific inhibition of C3 to facilitate general complement inhibition on endotoxin affinity sorbents for apheresis applications.
    Fowers KD; Janatova J
    Biomaterials; 2001 Jul; 22(13):1749-61. PubMed ID: 11396878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface Modification of Reduced Graphene Oxide Beads: Integrating Efficient Endotoxin Adsorption and Improved Blood Compatibility.
    Li Z; Yan X; Wu K; Jiao Y; Zhou C; Yang J
    ACS Appl Bio Mater; 2021 Jun; 4(6):4896-4906. PubMed ID: 35007038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B immobilized on cross-linked cellulose microspheres for endotoxin adsorption.
    Cao X; Zhu B; Zhang X; Dong H
    Carbohydr Polym; 2016 Jan; 136():12-8. PubMed ID: 26572323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of C3 in C3 glomerulopathy.
    Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
    Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted pH-regulated antigen 1 of Candida albicans blocks activation and conversion of complement C3.
    Luo S; Hartmann A; Dahse HM; Skerka C; Zipfel PF
    J Immunol; 2010 Aug; 185(4):2164-73. PubMed ID: 20644161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The apolipoprotein(a) moiety of lipoprotein(a) interacts with the complement activation fragment iC3b but does not functionally affect C3 activation or degradation.
    Seifert PS; Roth I; Zioncheck TF
    Atherosclerosis; 1992 Apr; 93(3):209-16. PubMed ID: 1534227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
    Subías Hidalgo M; Yébenes H; Rodríguez-Gallego C; Martín-Ambrosio A; Domínguez M; Tortajada A; Rodríguez de Córdoba S; Llorca O
    Eur J Immunol; 2017 Mar; 47(3):504-515. PubMed ID: 28083930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of induction of IL-1 production in human monocytes by complement fragments.
    Arend WP; Massoni RJ; Niemann MA; Giclas PC
    J Immunol; 1989 Jan; 142(1):173-8. PubMed ID: 2783323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulation-dependent inhibition of in vitro complement activation by anti-apo-B sepharose 4B CL.
    Kadar JG; Parusel M; Borberg H
    Infusionsther Transfusionsmed; 1992 Oct; 19(5):237-40. PubMed ID: 1288767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel endotoxin adsorbing materials, polymyxin-sepharose and polyporous polyethylene membrane for removal of endotoxin from dialysis systems.
    Umeda M; Niwa M; Yamagami S; Kishimot T; Maekawa M; Sawada Y
    Biomater Artif Cells Artif Organs; 1990; 18(4):491-7. PubMed ID: 2285811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and application of a novel ligand for affinity chromatography based removal of endotoxin from antibodies.
    McAllister LA; Hixon MS; Schwartz R; Kubitz DS; Janda KD
    Bioconjug Chem; 2007; 18(2):559-66. PubMed ID: 17315943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation on solid surfaces as determined by C3 deposition and hemolytic consumption.
    Liu L; Elwing H
    J Biomed Mater Res; 1994 Jul; 28(7):767-73. PubMed ID: 8083244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune complement activation on polystyrene and silicon dioxide surfaces. Impact of reversible IgG adsorption.
    Sellborn A; Andersson M; Hedlund J; Andersson J; Berglin M; Elwing H
    Mol Immunol; 2005 Mar; 42(5):569-74. PubMed ID: 15607815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of complement C3 activation products in human atherosclerotic lesions.
    Seifert PS; Messner M; Roth I; Bhakdi S
    Atherosclerosis; 1991 Nov; 91(1-2):155-62. PubMed ID: 1811551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capture of bacterial endotoxins using a supermacroporous monolithic matrix with immobilized polyethyleneimine, lysozyme or polymyxin B.
    Hanora A; Plieva FM; Hedström M; Galaev IY; Mattiasson B
    J Biotechnol; 2005 Sep; 118(4):421-33. PubMed ID: 16026882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modification of cellulose that facilitates the control of complement activation.
    Johnson RJ; Lelah MD; Sutliff TM; Boggs DR
    Blood Purif; 1990; 8(6):318-28. PubMed ID: 2151203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of polymyxin B endotoxin removal from extracorporeal blood flow: molecular interactions.
    Vesentini S; Soncini M; Fiore GB; Redaelli A
    Contrib Nephrol; 2010; 167():45-54. PubMed ID: 20519898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endotoxin apheresis for sepsis.
    Shimizu T; Endo Y; Tsuchihashi H; Akabori H; Yamamoto H; Tani T
    Transfus Apher Sci; 2006 Dec; 35(3):271-82. PubMed ID: 17118710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.